{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:41:00Z","timestamp":1782337260309,"version":"3.54.5"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>PsA increases cardiovascular disease risk. Emerging evidence suggests biologic DMARDs may offer protective effects, though their advantage over conventional therapy remains under investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted using the Chang Gung Memorial Research Database in Taiwan. Patients with PsA were identified from 2001 to 2022. The study included 2383 patients who had used at least one DMARDs, divided into two groups: 1190 on bDMARDs and 1193 on conventional DMARDs (cDMARDs). The primary outcome was defined as a major adverse cardiovascular event (MACE), including stroke, myocardial infarction, cardiovascular mortality or coronary revascularization. Potential confounding was mitigated using inverse probability of treatment weighting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The average follow-up period was 5.1\u2009years for the bDMARD group and 5.0\u2009years for the cDMARD group. The incidence of MACE was 0.34 and 0.55 events per 100 person-years in the bDMARDs and cDMARDs groups, respectively. All-cause mortality occurred at rates of 0.73 and 1.86 per 100 person-years in the bDMARDs and cDMARDs groups, respectively. The results showed that the bDMARDs group had lower risks of MACE (hazard ratio [HR]: 0.65; 95% CI: 0.43\u20130.96), all-cause mortality (HR: 0.44; 95% CI: 0.35\u20130.57) and cardiovascular mortality (HR: 0.54; 95% CI: 0.32\u20130.92), but a higher incidence of infection-related admission (subdistribution HR: 1.45; 95% CI: 1.18\u20131.78).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>bDMARDs may reduce cardiovascular events and mortality in PsA, but infection risks warrant close monitoring. Further research is needed to refine treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf487","type":"journal-article","created":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:41:13Z","timestamp":1760269273000},"source":"Crossref","is-referenced-by-count":1,"title":["The risk of cardiovascular events following treatment for PsA with a biological agent"],"prefix":"10.1093","volume":"65","author":[{"given":"Chung-Yuan","family":"Hsu","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital ,","place":["Taiwan"]},{"name":"Kaohsiung Municipal Feng Shan Hospital\u2014Under the management of Chang Gung Medical Foundation , Kaohsiung,","place":["Taiwan"]},{"name":"School of Medicine, College of Medicine, Chang Gung University , Taoyuan,","place":["Taiwan"]},{"name":"College of Medicine, National Sun Yat-sen University , Kaohsiung,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Hong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine , Kaohsiung,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7274-3458","authenticated-orcid":false,"given":"Yu-Jih","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital ,","place":["Taiwan"]},{"name":"School of Medicine, College of Medicine, Chang Gung University , Taoyuan,","place":["Taiwan"]},{"name":"College of Medicine, National Sun Yat-sen University , Kaohsiung,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lung","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital ,","place":["Taiwan"]},{"name":"Chang Gung University College of Medicine , Taoyuan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Keelung Chang Gung Memorial Hospital , Keelung,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-I","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital , Keelung,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0753-4529","authenticated-orcid":false,"given":"Tien-Ming","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Chang Gung University and Chang Gung Memorial Hospital , Taoyuan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Hsing","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine and the Center of Data Science and Biostatistics, Keelung Chang Gung Memorial Hospital , Keelung,","place":["Taiwan"]},{"name":"Chang Gung University School of Traditional Chinese Medicine, , Taoyuan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2026060719462386000_keaf487-B1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol Int"},{"key":"2026060719462386000_keaf487-B2","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"2026060719462386000_keaf487-B3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","article-title":"Cardiovascular risk in patients with psoriasis: JACC review topic of the week","volume":"77","author":"Garshick","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026060719462386000_keaf487-B4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076384","article-title":"Targeted therapies in psoriatic arthritis\u2014an update","volume":"24","author":"Sundanum","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026060719462386000_keaf487-B5","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/jdv.12768","article-title":"Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort","volume":"29","author":"Ahlehoff","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026060719462386000_keaf487-B6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","article-title":"The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis","volume":"51","author":"Yang","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026060719462386000_keaf487-B7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2174\/138161282004140213123505","article-title":"Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review","volume":"20","author":"Armstrong","year":"2014","journal-title":"Curr Pharm Des"},{"key":"2026060719462386000_keaf487-B8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study","volume":"61","author":"Pina Vegas","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026060719462386000_keaf487-B9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaad.2024.12.025","article-title":"Risk of major adverse cardiovascular events and venous thromboembolic events between patients with psoriasis or psoriatic arthritis on tumor necrosis factor inhibitors, interleukin 17 inhibitors, interleukin 12\/23 inhibitors, and interleukin 23 inhibitors: an emulated target trial analysis","volume":"92","author":"Chen","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026060719462386000_keaf487-B10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaad.2025.03.055","article-title":"Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: a retrospective cohort study","volume":"93","author":"Song","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026060719462386000_keaf487-B11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/pds.4713","article-title":"The Chang Gung Research Database\u2014a multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan","volume":"28","author":"Shao","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026060719462386000_keaf487-B12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bj.2017.08.002","article-title":"Chang Gung Research Database: a multi-institutional database consisting of original medical records","volume":"40","author":"Tsai","year":"2017","journal-title":"Biomed J"},{"key":"2026060719462386000_keaf487-B13","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"key":"2026060719462386000_keaf487-B14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2026060719462386000_keaf487-B15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00392-023-02291-4","article-title":"Cardiovascular events risk in patients with systemic autoimmune diseases: a prognostic systematic review and meta-analysis","volume":"113","author":"Asenjo-Lobos","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2026060719462386000_keaf487-B16","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1038\/s41598-021-87766-y","article-title":"The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study","volume":"11","author":"Hong","year":"2021","journal-title":"Sci Rep"},{"key":"2026060719462386000_keaf487-B17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s13555-024-01098-z","article-title":"Does systemic anti-psoriatic treatment impact the risk of cardiovascular disease? A review over cardiovascular imaging studies","volume":"14","author":"Kaiser","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026060719462386000_keaf487-B18","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1097\/RHU.0000000000001738","article-title":"Prevalence of metabolic syndrome in psoriatic arthritis: systematic literature review and results from the CARMA cohort","volume":"28","author":"Urruticoechea-Arana","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2026060719462386000_keaf487-B19","doi-asserted-by":"crossref","first-page":"590749","DOI":"10.3389\/fimmu.2020.590749","article-title":"Adipokines, cardiovascular risk, and therapeutic management in obesity and psoriatic arthritis","volume":"11","author":"Porta","year":"2020","journal-title":"Front Immunol"},{"key":"2026060719462386000_keaf487-B20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/ard-2023-224965","article-title":"Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study","volume":"83","author":"Exarchou","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026060719462386000_keaf487-B21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2020.08.032","article-title":"Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): a nested case-control analysis","volume":"84","author":"Langley","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026060719462386000_keaf487-B22","doi-asserted-by":"crossref","first-page":"1759720X241289201","DOI":"10.1177\/1759720X241289201","article-title":"Infections in psoriatic arthritis: association with treatment","volume":"16","author":"Vassilopoulos","year":"2024","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026060719462386000_keaf487-B23","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/rheumatology\/keab655","article-title":"Cardiovascular disease in psoriatic arthritis: facts and unmet needs","volume":"61","author":"Gialouri","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026060719462386000_keaf487-B24","first-page":"e60980","article-title":"The impact of interleukin-17 inhibitors on major adverse cardiovascular events in psoriasis or psoriatic arthritis patients naive to biologic agents: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Ni","year":"2024","journal-title":"Cureus"},{"key":"2026060719462386000_keaf487-B25","doi-asserted-by":"crossref","first-page":"742713","DOI":"10.3389\/fmed.2021.742713","article-title":"Update on cardiovascular risk and obesity in psoriatic arthritis","volume":"8","author":"Ram\u00edrez","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026060719462386000_keaf487-B26","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/annrheumdis-2015-207980","article-title":"Incidence and predictors for cardiovascular events in patients with psoriatic arthritis","volume":"75","author":"Eder","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf487\/64659147\/keaf487.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/6\/keaf487\/64659147\/keaf487.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/6\/keaf487\/64659147\/keaf487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T23:46:31Z","timestamp":1780875991000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf487\/8284833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf487","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2025,10,13]]},"article-number":"keaf487"}}